Purpose: To assess which antiepileptic medications (AEDs) have the best evidence for long-term efficacy or effectiveness as initial monotherapy for patients with newly diagnosed or untreated epilepsy. Methods: A 10-member subcommission of the Commission on Therapeutic Strategies of The International League Against Epilepsy (ILAE), including adult and pediatric epileptologists, clinical pharmacologists, clinical trialists, and a statistician evaluated available evidence found through a structured literature review including MEDLINE, Current Contents and the Cochrane Library for all applicable articles from 1940 until July 2005. Articles dealing with different seizure types (for different age groups) and two epilepsy syndromes were assessed for quality of evidence (four classes) based on predefined criteria. Criteria for class I classification were a double-blind randomized controlled trial (RCT) design, ≥48-week treatment duration without forced exit criteria, information on ≥24-week seizure freedom data (efficacy) or ≥48-week retention data (effectiveness), demonstration of superiority or 80% power to detect a ≤20% relative difference in efficacy/effectiveness versus an adequate comparator, and appropriate statistical analysis. Class II studies met all class I criteria except for having either treatment duration of 24 to 47 weeks or, for noninferiority analysis, a power to only exclude a 21-30% relative difference. Class III studies included other randomized double-blind and open-label trials, and class IV included other forms of evidence (e.g., expert opinion, case reports). Quality of clinical trial evidence was used to determine the strength of the level of recommendation. Results: A total of 50 RCTs and seven meta-analyses contributed to the analysis. Only four RCTs had class I evidence, whereas two had class II evidence; the remainder were evaluated as class III evidence. Three seizure types had AEDs with level A or level B efficacy and effectiveness evidence as initial monotherapy: adults with partial-onset seizures (level A, carbamazepine and phenytoin; level B, valproic acid), children with partial-onset seizures (level A, oxcarbazepine; level B, None), and elderly adults with partial-onset seizures (level A, gabapentin and lamotrigine; level B, None). One adult seizure type [adults with generalized-onset tonic-clonic (GTC) seizures], two pediatric seizure types (GTC seizures and absence seizures), and two epilepsy syndromes (benign epilepsy with centrotemporal spikes and juvenile myoclonic epilepsy) had no AEDs with level A or level B efficacy and effectiveness evidence as initial monotherapy. Conclusions: This evidence-based guideline focused on AED efficacy or effectiveness as initial monotherapy for patients with newly diagnosed or untreated epilepsy. The absence of rigorous comprehensive adverse effects data makes it impossible to develop an evidence-based guideline aimed at identifying the overall optimal recommended initial-monotherapy AED. There is an especially alarming lack of well-designed, properly conducted RCTs for patients with generalized seizures/epilepsies and for children in general. The majority of relevant existing RCTs have significant methodologic problems that limit their applicability to this guideline's clinically relevant main question. Multicenter, multinational efforts are needed to design, conduct and analyze future clinically relevant RCTs that can answer the many outstanding questions identified in this guideline. The ultimate choice of an AED for any individual patient with newly diagnosed or untreated epilepsy should include consideration of the strength of the efficacy and effectiveness evidence for each AED along with other variables such as the AED safety and tolerability profile, pharmacokinetic properties, formulations, and expense. When selecting a patient's AED, physicians and patients should consider all relevant variables and not just efficacy and effectiveness. © 2006 International League Against Epilepsy.47710941120Definition of key terms (1990) Clinical Practice Guidelines: Directions for a New Program, pp. 33-51. , Field MJ, Lohr KN, eds. Washington, DC: National Academy PressProposal for revised clinical and electroencephalographic classification of epileptic seizures (1981) Epilepsia, 22, pp. 489-501Proposal for revised classification of epilepsies and epileptic syndromes (1989) Epilepsia, 30, pp. 389-399Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy (1998) Epilepsia, 39, pp. 799-803Chadwick, D., Monotherapy clinical trials of new antiepileptic drugs: Design, indications, and controversies (1997) Epilepsia, 38 (9 SUPPL.), pp. S16-20Schulz, K.F., Chalmers, I., Hayes, R.J., Altman, D.G., Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials (1995) JAMA, 273, pp. 408-412Schulz, K.F., Grimes, D.A., Allocation concealment in randomised trials: Defending against deciphering (2002) Lancet, 359, pp. 614-618Schulz, K.F., Grimes, D.A., Blinding in randomised trials: Hiding who got what (2002) Lancet, 359, pp. 696-700Chadwick, D., Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: A multicentre randomised DB study: Vigabatrin European Monotherapy Study Group (1999) Lancet, 354, pp. 13-19Chan, I.S., Exact tests of equivalence and efficacy with a non-zero lower bound for comparative studies (1998) Stat Med, 17, pp. 1403-1413(2003) Version 6 with Cytel StudioTM Statistical Software for Exact Nonparametric Inference, , Cambridge, Mass: CYTEL Software CorporationAcute pain management: Operative or medical procedures and trauma (1993) Clinical Practice Guideline No. 1, p. 107. , Agency for Healthcare Policy and Research Research, Rockville, Md: Agency for Healthcare Policy and ResearchEdlund, W., Gronseth, G., So, Y., Franklin, G., (2004) American Academy of Neurology Clincal Practice Guideline Process Manual, , St. Paul, Minn.: American Academy of NeurologyFrench, J.A., Kanner, A.M., Bautista, J., Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new onset epilepsy: Report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American Academy of Neurology and the American Epilepsy Society (2004) Neurology, 62, pp. 1252-1260French, J.A., Kanner, A.M., Bautista, J., Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society (2004) Epilepsia, 45, pp. 401-409Consensus statements: Medical management of epilepsy (1998) Neurology, 51 (5 SUPPL. 4), pp. S39-43Ross, S.D., Estok, R., Chopra, S., French, J., Management of newly diagnosed patients with epilepsy: A systematic review of the literature (2001) Evid Rep Technol Assess (Summ), 39, pp. 1-3Armijo, J.A., Sanchez, B., Gonzalez, A.B., Evidence based treatment of epilepsy (2002) Rev Neurol, 35 (1 SUPPL.), pp. S59-73Ramsay, R.E., DeToledo, J., Tonic-clonic seizures: A systematic review of antiepilepsy drug efficacy and safety (1997) Clin Ther, 19, pp. 433-446Posner, E.B., Mohamed, K., Marson, A.G., A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine (2005) Seizure, 14, pp. 1179-1222Practice parameter: Management issues for women with epilepsy (1998) Epilepsia, 39, pp. 1226-1231Practice parameter: Management issues for women with epilepsy (1998) Neurology, 51, pp. 944-948Clinical guidelines for the management of epilepsy in adults with an intellectual disability (2001) Seizure, 10, pp. 401-409Camfield, P., Camfield, C., Childhood epilepsy: What is the evidence for what we think and what we do? (2003) J Child Neurol, 18, pp. 272-287Gram, L., Bentsen, K.D., Parnas, J., Controlled trials in epilepsy: A review (1982) Epilepsia, 23, pp. 491-519Cochrane, H.C., Marson, A.G., Baker, G.A., Chadwick, D.W., Neuropsychological outcomes in randomized controlled trials of antiepileptic drugs: A systematic review of methodology and reporting standards (1998) Epilepsia, 39, pp. 1088-1097Brunbech, L., Sabers, A., Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: A comparative review of newer versus older agents (2002) Drugs, 62, pp. 593-604Baker, G.A., Hesdon, B., Marson, A.G., Quality-of-life and behavioral outcome measures in randomized controlled trials of antiepileptic drugs: A systematic review of methodology and reporting standards (2000) Epilepsia, 41, pp. 1357-1363Kotsopoulos, I.A., Evers, S.M., Ament, A.J., De Krom, M.C., Estimating the costs of epilepsy: An international comparison of epilepsy cost studies (2001) Epilepsia, 42, pp. 634-640Levy, P., Economic evaluation of antiepileptic drug therapy: A methodologic review (2002) Epilepsia, 43, pp. 550-558Mattson, R.H., Cramer, J.A., Collins, J.F., Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures (1985) N Engl J Med, 313, pp. 145-151Turnbull, D.M., Howel, D., Rawlins, M.D., Chadwick, D.W., Which drug for the adult epileptic patient: Phenytoin or valproate? (1985) Br Med J (Clin Res Ed), 290, pp. 815-819Dam, M., Ekberg, R., Loyning, Y., A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy (1989) J Neurol Neurosurg Psychiatry, 52, pp. 472-476Mattson, R.H., Cramer, J.A., Collins, J.F., A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults: The Department of Veterans Affair's Epilepsy Cooperative Study No. 264 Group (1992) N Engl J Med, 327, pp. 765-771Richens, A., Davidson, D.L., Cartridge, N.E., Easter, D.J., A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy: Adult EPITEG Collaborative Group (1994) J Neurol Neurosurg Psychiatry, 57, pp. 682-687Heller, A.J., Chesterman, P., Elwes, R.D., Phenobarbitone, phenytoin, carbamazepine or sodium valproate for newly diagnosed adult epilepsy: A randomised comparative monotherapy trial (1995) J Neurol Neurosurg Psychiatry, 58, pp. 44-50Brodie, M., Richens, A., Yuen, A.W., Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy: UK Lamotrigine/Carbamazepine Monotherapy Trial Group (1995) Lancet, 345, pp. 476-479Bill, P.A., Vigonius, U., Pohlmann, H., A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy (1997) Epilepsy Res, 27, pp. 195-204Christe, W., Kramer, G., Vigonius, U., A double-blind controlled clinical trial: Oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy (1997) Epilepsy Res, 26, pp. 451-460Chadwick, D.W., Anhut, H., Greiner, M.J., A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures: International Gabapentin Monotherapy Study Group 945-77 (1998) Neurology, 51, pp. 1282-1288Steiner, T.J., Dellaportas, C.I., Findley, L.J., Lamotrigine monotherapy in newly diagnosed untreated epilepsy: A double-blind comparison with phenytoin (1999) Epilepsia, 40, pp. 601-607Gilliam, F.G., Veloso, F., Bomhof, M.A., A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy (2003) Neurology, 60, pp. 196-202Privitera, M.D., Brodie, M.J., Mattson, R.H., Topiramate, carbamazepine and valproate monotherapy: Double-blind comparison in newly diagnosed epilepsy (2003) Acta Neurol Scand, 107, pp. 165-175Arroyo, S., Dodson, W.E., Privitera, M.D., A Randomized dose-controlled study of topiramate as first-line therapy in epilepsy (2005) Acta Neurol Scand, 112, pp. 214-222(2004) Trileptal Prescribing Information, , East Hanover, New JerseyNieto-Barrera, M., Brozmanova, M., Capovilla, G., A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy (2001) Epilepsy Res, 46, pp. 145-155Mikkelsen, B., Berggreen, P., Joensen, P., Clonazepam (Rivotril) and carbamazepine (Tegretol) in psychomotor epilepsy: A randomized multicenter trial (1981) Epilepsia, 22, pp. 415-420Ramsay, R.E., Wilder, B.J., Berger, J.R., Bruni, J., A double-blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults (1983) Neurology, 33, pp. 904-910Brodie, M.J., Chadwick, D.W., Anhut, H., Gabapentin versus lamotrigine monotherapy: A double-blind comparison in newly diagnosed epilepsy (2002) Epilepsia, 43, pp. 993-1000Callaghan, N., Kenny, R.A., O'Neill, B., A prospective study between carbamazepine, phenytoin, and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy (1985) J Neurol Neurosurg Psychiatry, 48, pp. 639-644Reunanen, M., Dam, M., Yuen, A.W., A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy (1996) Epilepsy Res, 23, pp. 149-155Loiseau, P., Cohadon, S., Jogeix, M., Efficacy of sodium valproate in partial epilepsy: Crossed study of valproate and carbamazepine (1984) Rev Neurol (Paris), 140, pp. 434-437Turnbull, D.M., Rawlins, M.D., Weightman, D., Chadwick, D.W., A comparison of phenytoin and valproate in previously untreated adult epileptic patients (1982) J Neurol Neurosurg Psychiatry, 45, pp. 55-59Placencia, M., Sander, J.W., Shorvon, S.D., Antiepileptic drug treatment in a community health care setting in northern Ecuador: A prospective 12-month assessment (1993) Epilepsy Res, 14, pp. 237-244Kalviainen, R., Aikia, M., Saukkonen, A.M., Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy: A randomized, controlled study (1995) Arch Neurol, 52, pp. 989-996Gibberd, F.B., Park, D.M., Scott, G., A comparison of phenytoin and pheneturide in patients with epilepsy: A double-blind cross-over trial (1982) J Neurol Neurosurg Psychiatry, 45, pp. 1113-1118Sommerfeld-Ziskin, The effect of phenobarbital on the mentality of epileptic patients (1940) Arch Neurol Psychiatry, 43, pp. 70-79Feksi, A.T., Kaamugisha, J., Gatiti, S., Comprehensive primary health care antiepileptic drug treatment programme in rural and semi-urban Kenya: ICBERG (International Community-based Epilepsy Research Group) (1991) Lancet, 337, pp. 406-409Shakir, R.A., Johnson, R.H., Lambie, D.G., Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy (1981) Epilepsia, 22, pp. 27-33Rastogi, P., Mehrotra, T.N., Agarwala, R.K., Singh, V.S., Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy (1991) J Assoc Physicians India, 39, pp. 606-608Tanganelli, P., Regesta, G., Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: A randomized response conditional cross-over study (1996) Epilepsy Res, 25, pp. 257-262Prevey, M.L., Delaney, R.C., Cramer, J.A., Effect of valproate on cognitive functioning: Comparison with carbamazepine: The Department of Veterans Affairs Epilepsy Cooperative Study 264 Group (1996) Arch Neurol, 53, pp. 1008-1016Pulliainen, V., Jokelainen, M., Effects of phenytoin and carbamazepine on cognitive functions in newly diagnosed epileptic patients (1994) Acta Neurol Scand, 89, pp. 81-86Pulliainen, V., Jokelainen, M., Comparing the cognitive effects of phenytoin and carbamazepine in long-term monotherapy: A two-year follow-up (1995) Epilepsia, 36, pp. 1195-1202Aikia, M., Kalviaïnen, R., Sivenius, J., Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: One year follow-up (1992) Epilepsy Res, 11, pp. 199-203Brodie, M.J., Wroe, S.J., Dean, A.D., Efficacy and safety of remacemide versus carbamazepine in newly diagnosed epilepsy: Comparison by sequential analysis (2002) Epilepsy Behav, 3, pp. 140-146Marson, A.G., Williamson, P.R., Clough, H., Carbamazepine versus valproate monotherapy for epilepsy: A meta-analysis (2002) Epilepsia, 43, pp. 505-513Tudur Smith, C., Marson, A.G., Clough, H.E., Williamson, P.R., Carbamazepine versus phenytoin monotherapy for epilepsy (2002) Cochrane Database Syst Rev, pp. CD001911Tudur Smith, C., Marson, A.G., Williamson, P.R., Phenytoin versus valproate monotherapy for partial onset seizures and generalized onset tonic-clonic seizures (2001) Cochrane Database Syst Rev, pp. CD001769Taylor, S., Tudur Smith, C., Williamson, P.R., Marson, A.G., Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures (2001) Cochrane Database Syst Rev, pp. CD002217Tudur Smith, C., Marson, A.G., Williamson, P.R., Carbamazepine versus phenobarbitone monotherapy for epilepsy (2003) Cochrane Database Syst Rev, pp. CD001904Whitehead, J., Stevens, J., Brodie, M., Remacemide versus carbamazepine in newly diagnosed epilepsy (2002) Epilepsy Beh, 3, pp. 405-406Verity, C.M., Hosking, G., Easter, D.J., A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy: The Paediatric EPITEG Collaborative Group (1995) Dev Med Child Neurol, 37, pp. 97-108De Silva, M., MacArdle, B., McGowan, M., Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy (1996) Lancet, 347, pp. 709-713Guerreiro, M.M., Vigonius, U., Pohlmann, H., A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy (1997) Epilepsy Res, 27, pp. 205-213Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy: Canadian Study Group for Childhood Epilepsy (1998) Epilepsia, 39, pp. 952-959Pal, D.K., Das, T., Chaudhury, G., Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India (1998) Lancet, 351, pp. 19-23Wheless, J.W., Neto, W., Wang, S., Topiramate, carbamazepine, and valproate monotherapy: Double-blind comparison in children with newly diagnosed epilepsy (2004) J Child Neurol, 19, pp. 135-141Zamponi, N., Cardinali, C., Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children (1999) Arch Neurol, 56, pp. 605-607Dodson, W.E., Carbamazepine efficacy and utilization in children (1987) Epilepsia, 28 (3 SUPPL.), pp. S17-24Young, R.S., Alger, P.M., Bauer, L., Lauderbaugh, D., A randomized, double-blind, crossover study of phenobarbital and mephobarbital (1986) J Child Neurol, 1, pp. 361-363Mitchell, W.G., Chavez, J.M., Carbamazepine versus phenobarbital for partial onset seizures in children (1987) Epilepsia, 28, pp. 56-60Nolte, R.W., Brugmann, B., Britzinger, G., Effects of phenytoin- and primidone-induced monotherapy on mental performance in children, in antiepileptic therapy (1980) Advances in Drug Monitoring, , Johannssen SI, ed. New York: Raven PressChen, Y.J., Kang, W.M., So, W.C., Comparison of antiepileptic drugs on cognitive function in newly diagnosed epileptic children: A psychometric and neurophysiological study (1996) Epilepsia, 37, pp. 81-86Forsythe, I., Butler, R., Berg, I., McGuire, R., Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate (1991) Dev Med Child Neurol, 33, pp. 524-534Berg, I., Butler, A., Ellis, M., Foster, J., Psychiatric aspects of epilepsy in childhood treated with carbamazepine, phenytoin or sodium valproate: A random trial (1993) Dev Med Child Neurol, 35, pp. 149-157Glauser, T.A., Dlugos, D.J., Dodson, W.E., A Double-blind Dose-controlled Study Evaluated Topiramate As Monotherapy in 470 Patients with Newly Diagnosed (≤3 Months) Epilepsy or Epilepsy Relapse in the Absence of Therapy, , in pressRowan, A.J., Ramsay, R.E., Collins, J.F., New onset geriatric epilepsy: A randomized study of gabapentin, lamotrigine, and carbamazepine (2005) Neurology, 64, pp. 1868-1873Brodie, M.J., Overstall, P.W., Giorgi, L., Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy: The UK Lamotrigine Elderly Study Group (1999) Epilepsy Res, 37, pp. 81-87Craig, I., Tallis, R., Impact of valproate and phenytoin on cognitive function in elderly patients: Results of a single-blind randomized comparative study (1994) Epilepsia, 35, pp. 381-390Ramsay, R.E.W., Murphy, B.J., Holmes, J.V., Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic-clonic seizures (1992) J Epilepsy, 5, pp. 55-60Perucca, E., Gram, L., Avanzini, G., Dulac, O., Antiepileptic drugs as a cause of worsening seizures (1998) Epilepsia, 39, pp. 5-17Shields, W., Saslow, E., Myoclonic, atonic and absence seizures following institution of carbamazepine therapy in children (1983) Neurology, 33, pp. 1487-1489Guerrini, R., Belmonte, A., Genton, P., Antiepileptic drug-induced worsening of seizures in children (1998) Epilepsia, 39 (3 SUPPL.), pp. S2-10Genton, P., When antiepileptic drugs aggravate epilepsy (2000) Brain Dev, 22, pp. 75-80Thilothammal, N., Banu, K., Ratnam, R.S., Comparison of phenobarbitone, phenytoin with sodium valproate: Randomized, double-blind study (1996) Indian Pediatr, 33, pp. 549-555Trudeau, V., Myers, S., LaMoreaux, L., Gabapentin in naive childhood absence epilepsy: Results from two double-blind, placebo-controlled, multicenter studies (1996) J Child Neurol, 11, pp. 470-475Frank, L.M., Enlow, T., Holmes, G.L., Lamictal (lamotrigine) monotherapy for typical absence seizures in children (1999) Epilepsia, 40, pp. 973-979Callaghan, N., O'Hare, J., O'Driscoll, D., Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal) (1982) Dev Med Child Neurol, 24, pp. 830-836Sato, S., White, B.G., Penry, J.K., Valproic acid versus ethosuximide in the treatment of absence seizures (1982) Neurology, 32, pp. 157-163Martinovic, Z., Comparison of ethosuximide with sodium valproate (1983) Advances in Epileptology, pp. 301-305. , Parsonage M. et al., eds. New York: XIVth Epilepsy International Symposium, Raven PressCoppola, G., Auricchio, G., Federico, R., Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: An open-label, randomized, parallel-group study (2004) Epilepsia, 45, pp. 1049-1053Posner, E.B., Mohamed, K., Marson, A.G., Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents (2003) Cochrane Database Syst Rev, pp. CD003032Callaghan, N., Odriscoll, D., Daley, M., A comparative study between ethosuximide and sodium valproate in the treatment of petit mal epilepsy (1980) Royal Society of Medicine International Congress and Symposium, No. 30: The Place of Sodium Valproate in the Treatment of Epilepsy, pp. 47-52. , London: Academic PressRating, D., Wolf, C., Bast, T., Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: A 6-month randomized, double-blind, placebo- controlled study: Sulthiame Study Group (2000) Epilepsia, 41, pp. 1284-1288Mitsudome, A., Ohfu, M., Yasumoto, S., The effectiveness of clonazepam on the Rolandic discharges (1997) Brain Dev, 19, pp. 274-278Bourgeois, B., Gabapentin (Neurontin) monotherapy in children with benign childhood epilepsy with centrotemporal spikes (BECTS): A 36-week, double-blind, placebo-controlled study (1998) Epilepsia, 39 (6 SUPPL.), p. 163Ma, C.K., Chan, K.Y., Benign childhood epilepsy with centrotemporal spikes: A study of 50 Chinese children (2003) Brain Dev, 25, pp. 390-395Dulac, O., Figueroa, D., Rey, E., Arthuis, M., Monotherapy with clobazam in epilepsies in children (1983) Presse Med, 12, pp. 1067-1069Barron, T.F., Hunt, S.L., Hoban, T.F., Price, M.L., Lamotrigine monotherapy in children (2000) Pediatr Neurol, 23, pp. 160-163Bello-Espinosa, L.E., Roberts, S.L., Levetiracetam for benign epilepsy of childhood with centrotemporal spikes: Three cases (2003) Seizure, 12, pp. 157-159Sundqvist, A., Tomson, T., Lundkvist, B., Valproate as monotherapy for juvenile myoclonic epilepsy: Dose-effect study (1998) Ther Drug Monit, 20, pp. 149-157Sundqvist, A., Nilsson, B.Y., Tomson, T., Valproate monotherapy in juvenile myoclonic epilepsy: Dose-related effects on electroencephalographic and other neurophysiologic tests (1999) Ther Drug Monit, 21, pp. 91-96Timmings, P.R., A. Efficacy of lamotrigine as monotherapy for juvenile myoclonic epilepsy: Pilot study results in 20th IEC (1993) Epilepsia, 34 (2 SUPPL.), p. 160Obeid, T., Panayiotopoulos, C.P., Clonazepam in juvenile myoclonic epilepsy (1989) Epilepsia, 30, pp. 603-606Smith, K.B., Pritchett, T., Levetiracetam, a promising option for the treatment of juvenile myoclonic epilepsy (2000) Epilepsia, 41, p. 39Buchanan, N., The use of lamotrigine in juvenile myoclonic epilepsy (1996) Seizure, 5, pp. 149-151Carrazana, E.J., Wheeler, S.D., Exacerbation of juvenile myoclonic epilepsy with lamotrigine (2001) Neurology, 56, pp. 1424-1425Rosenfeld, W., Topiramate in patients with juvenile myoclonic epilepsy (1998) Epilepsia, 39 (6 SUPPL.), pp. S139Mullin, P.S.J.M., Effectiveness of open-label zonisamide in juvenile myoclonic epilepsy (2001) Epilepsia, 42 (7 SUPPL.), p. 184Atakli, D., Sozuer, D., Atay, T., Misdiagnosis and treatment in juvenile myoclonic epilepsy (1998) Seizure, 7, pp. 63-66Bourgeois, B., Monotherapy with VPA in primary generalized epilepsy (1987) Epilepsia, 28 (2 SUPPL.), pp. S8-S11Delgado-Escueta, A.V., Enrile-Bacsal, F., Juvenile myoclonic epilepsy of Janz (1984) Neurology, 34, pp. 285-294Fernando-Dongas, M.C., Radtke, R.A., Vanlandingham, K.E., Husain, A.M., Characteristics of valproic acid resistant juvenile myoclonic epilepsy (2000) Seizure, 9, pp. 385-388Janz, D., Ruckfall: Prognose nach reduction der medikamente bei epilepsiebehandling (1983) Nervenarzt, 54, pp. 525-529Kleveland, G., Engelsen, B.A., Juvenile myoclonic epilepsy: Clinical characteristics, treatment and prognosis in a Norwegian population of patients (1998) Seizure, 7, pp. 31-38Penry, J.K., Dean, J.C., Riela, A.R., Juvenile myoclonic epilepsy: Long-term response to therapy (1989) Epilepsia, 30 (4 SUPPL.), pp. S19-23Sharpe, C., Buchanan, N., Juvenile myoclonic epilepsy: Diagnosis, management and outcome (1995) Med J Aust, 162, pp. 133-134Biraben, A., Allain, H., Scarabin, J.M., Exacerbation of juvenile myoclonic epilepsy with lamotrigine (2000) Neurology, 55, p. 1758